Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery – significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer (NSCLC).
Biosyngen receives FDA approval to start Phase I trial for TCR therapy – Pharmaceutical Technology
Biosygen also has two other T-cell therapies in Phase I/II clinical development. Image Credit: Juan Gaertner / Shutterstock. Biosyngen received an all-clear from the US
September 11, 2023